



Patient and provider factors associated with the noninitiation of tamoxifen for young women at high-risk for the development of breast cancer

Pridvi Kandagatla MD^{1,2}  | Natalie N. Rizk MD, PhD¹ | Danijela Dokic MD³ |
 Jeannie Kochkodan BA⁴ | Samantha Estevez MD⁵ | Megan Yanik BA⁴ | Sowmya Goranta MD⁶ |
 Kathryn Huber-Keener MD, PhD⁷  | Jacqueline S. Jeruss MD, PhD¹

¹Surgery, University of Michigan, Ann Arbor, Michigan

²Surgery, Henry Ford Hospital, Detroit, Michigan

³Medicine, Mercy Hospital, Chicago, Illinois

⁴University of Michigan School of Medicine, Ann Arbor, Michigan

⁵Ob/Gyn, Zucker School of Medicine, Hempstead, New York

⁶Internal Medicine, Michigan State University, Flint, Michigan

⁷Ob/Gyn, University of Iowa, Iowa City, Iowa

Correspondence

Jacqueline S. Jeruss, Department of Surgery, University of Michigan, Ann Arbor, MI.
 Email: jjeruss@med.umich.edu

Funding information

Stichting A Sister's Hope; National Institute of Health, Grant/Award Number: R01CA214384 and T32CA009672

Abstract

We sought to identify factors associated with disparities in tamoxifen utilization among young patients at high-risk for developing breast cancer. We identified 67 premenopausal, high-risk women age 35-45, without surgical prophylaxis, who did not initiate tamoxifen. Factors associated with noninitiation were examined. About 37% of patients had no documented provider-based discussion regarding initiation. Type of high-risk diagnosis was the only factor associated with a provider-based discussion ($P = .03$). For patients offered tamoxifen, primary reasons for noninitiation were perceived minimal benefit (66.7%), fertility concerns (16.7%), and concerns about side effects (7.1%). Implementation of comprehensive educational strategies regarding the benefits of tamoxifen should be facilitated to improve initiation among young high-risk patients.

KEYWORDS

chemoprevention, shared decision making, tamoxifen

1 | INTRODUCTION

Breast cancer is the most common cancer affecting women across the world, and the leading cause of cancer-related death. Given the high incidence of breast cancer, effort has been placed on sensitive and specific screening strategies as well as the identification of high-risk patients. Through these strategies and implementation of antihormonal agents such as tamoxifen, prevention of breast cancer is possible. The NSABP P-1 Trial showed that the use of tamoxifen reduced the risk of estrogen receptor positive breast cancer by 49% among high-risk patients.¹ As a result, tamoxifen is currently recommended as a chemopreventative agent for women with an elevated breast cancer risk.^{2,3} The current indications for tamoxifen as chemoprevention include patients diagnosed with atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), a BRCA

mutation, lobular carcinoma in situ (LCIS), flat epithelial atypia (FEA), or a strong family history.⁴

Given the long-term benefits of tamoxifen, young high-risk women may be a patient population that stands to obtain the greatest benefit. Despite this potential benefit, the number of eligible women, particularly young women, undergoing tamoxifen chemoprevention therapy is low.⁵ The decision to initiate tamoxifen chemoprevention is complex, and multiple barriers and characteristics associated with the utilization of this therapy have been reported.^{6,7} In this study, we sought to identify factors associated with tamoxifen noninitiation among young patients with an increased risk for the development of breast cancer. With a thorough understanding of these deterring factors, providers may be able to help implement effective interventions to address these factors and increase tamoxifen initiation among young high-risk women.

2 | METHODS

2.1 | Patient selection

With IRB approval, we identified women treated at Northwestern Memorial Hospital (Chicago, IL) who were younger than 46 years and received a high-risk diagnosis (BRCA mutation, LCIS, ADH, ALH, FEA, strong family history) between 2007 and 2012, for whom adjuvant tamoxifen was indicated, but was not initiated. Strong family history of breast cancer included first-degree female relatives. A total of 239 patients were identified. Patients who opted for surgical prophylaxis (bilateral mastectomy, bilateral oophorectomy), received a cancer diagnosis, or who initiated tamoxifen use were excluded (n = 91). Additionally, women younger than 35 years (n = 81) for whom tamoxifen was not indicated were excluded.

2.2 | Chart review

Patient charts were reviewed for demographics, fertility concerns, and high-risk stratification. Collected data had been documented

TABLE 1 High-risk breast cancer diagnosis

High-risk diagnosis	
ADH	20 (29.9%)
ALH	7 (10.4%)
BRCA1+	12 (17.9%)
BRCA2+	9 (13.4%)
Family Hx	3 (4.5%)
FEA	4 (6.0%)
LCIS	12 (17.9%)
Family history of breast cancer	
Positive	46 (68.7%)
Negative	21 (31.3%)
Family history of ovarian cancer	
Positive	16 (23.9%)
Negative	51 (76.1%)
Genetic mutation status	
BRCA1+	12 (17.9%)
BRCA2+	9 (13.4%)
No genetic mutation	17 (25.4%)
Declined genetic testing	29 (43.3%)
History of breast biopsy	
Yes	44 (65.7%)
No	23 (34.3%)
History of breast MRI	
Yes	20 (29.9%)
No	47 (70.1%)

High-risk breast cancer diagnosis characteristics in patients who did not initiate tamoxifen including the type of high-risk diagnosis, family history of breast cancer, patient history of genetic testing, MRI, and/or biopsy.

TABLE 2 Physician discussion of tamoxifen initiation

	Discussed	No documented discussion	P-value
n (%)	42 (62.7%)	25 (37.3%)	
Mean age (SD)	41.3 (2.9)	40.7 (3.2)	0.44
Diagnosis			
ADH/ALH	19 (47.6)	8 (36.0)	0.03
BRCA 1 + /2 +	8 (14.3)	13 (48.0)	
Family history	3 (9.5)	0 (4.0)	
FEA	2 (7.1)	2 (8.0)	
LCIS	10 (21.4)	2 (4.0)	
Race (%)			
White	23 (54.8)	19 (76.0)	0.47
Black	4 (9.5)	2 (8.0)	
Asian	2 (4.8)	0 (0.0)	
Other	4 (9.5)	2 (8.0)	
Declined	9 (21.4)	2 (8.0)	
Ethnicity (%)			
Hispanic	8 (19.0)	2 (8.0)	0.41
Non-hispanic	28 (66.7)	20 (80.0)	
Declined	6 (14.3)	3 (12.0)	
Marital status (%)			
Single	11 (26.2)	5 (20.0)	0.67
Married	28 (66.7)	17 (68.0)	
Separated/ divorced/ widowed	3 (7.1)	3 (12.0)	
Alcohol use (%)	25 (59.5)	16 (64.0)	0.72
Smoking (%)			
Never	30 (71.4)	21 (84.0)	0.65
Former	8 (19.0)	3 (12.0)	
Current	3 (7.1)	1 (4.0)	
Unknown	1 (2.4)	0 (0.0)	
Insurance (%)			
None	14 (33.3)	6 (24.0)	0.26
Private	27 (64.3)	16 (64.0)	
Public	1 (2.4)	3 (12.0)	
Family history (%)			
None	13 (31.0)	8 (32.0)	0.61
1st degree relative	18 (42.9)	8 (32.0)	
Non-1st degree relative	11 (26.2)	9 (36.0)	
Anxiety (%)	7 (16.7)	4 (16.0)	1.00
Obesity (%)	4 (9.5)	4 (16.0)	0.46
Nulliparous (%)	24 (57.1)	13 (52.0)	0.50

Abbreviations: ADH, atypical ductal hyperplasia; ALH, atypical lobular hyperplasia; FEA, flat epithelial atypia; LCIS, lobular carcinoma in situ; SD, standard deviation.

Statistically significant value is indicated in bold font.

in the EMR through standardized formal Breast Cancer intake forms. Since the establishment of the Oncofertility program at Northwestern Memorial Hospital in 2007, a prompt was placed in the EMR, requiring oncologists to ask premenopausal patients about interest in fertility preservation prior to completing the medical record and the initiation of therapy. This information also was collected and compiled from providers' notes. Reviewing oncology notes and cross-referencing with pharmacies for patient's prescription data, tamoxifen use was also recorded. We examined the baseline demographic characteristics for the study patients and identified patient reasons for tamoxifen noninitiation. We also stratified the study patients by their high-risk diagnoses. A lack of documented discussion regarding tamoxifen indications or initiation were also noted. We performed Chi-Square tests with a significance value of 0.05 to identify patient factors associated with a lack of documented discussion regarding tamoxifen initiation.

3 | RESULTS

We included a total of 67 patients in the study. The median age was 41 (range 35-45) and majority of the patients were white (62.7%). The preponderance of the patients in our study held a high-risk diagnosis of ADH (29.9%) followed by LCIS (17.9%) and BRCA 1 mutations (17.9%) (Table 1). Patients who had a high-risk diagnosis from biopsy-proven pathology and family history were categorized by biopsy-proven pathology. Patients who had only a family history of breast cancer and no pathologic or genetic diagnosis ($n = 3$, 4.5%) were listed as "Family History." Of all of the patients with a high-risk diagnosis, the majority (68.7%) did have a family history of breast cancer. In the study population, 43.3% of patients opted to forgo genetic testing. Of the 38 patients that were tested, 17 (44.7%) had no genetic mutation, 9 (23.7%) had a BRCA 2 mutation, and 12 (31.6%) had BRCA 1 mutation. Most of the patients in our study did not have a breast MRI (70.1%), but had breast biopsy (65.7%). Table 2 shows comparisons between characteristics for patients that had a documented provider discussion regarding tamoxifen initiation and those that did not. There were no significant differences in patient demographics between the two groups.

There was an association between patients with a tissue diagnosis (ADH/ALH or LCIS) and a documented provider discussion about tamoxifen ($P = .03$).

3.1 | Reasons for tamoxifen noninitiation

Reasons for tamoxifen noninitiation were stratified into five categories (Figure 1 and Figure 2). The most common reason for noninitiation was a perception of little benefit (41.8%). Despite the indications for tamoxifen, 37.3% of patients did not have a documented discussion with a provider regarding treatment risks and benefits. Results were further stratified into reasons for declining tamoxifen among patients who had a documented discussion. The primary reason high-risk women (66.7%) declined tamoxifen was perception of little benefit. Declining tamoxifen for fertility concerns (16.7%) was the second most prevalent reason. A relatively low number of high-risk women declined tamoxifen secondary to concerns about side effects (7.1%).

4 | DISCUSSION

Considering the vast amount of data detailing the preventive benefit of tamoxifen for high-risk patients, it is concerning that the most common reason for underutilization in our study was perception of little benefit. A possible explanation could be a lack of information provided to high-risk patients. However, Fagerlin found that the perception of little benefit persisted even after providing patients with a decision aid outlining the risks and benefits of tamoxifen for chemoprevention.⁸ These findings were similar to those found by Port showing that educational sessions did not affect patients' decisions regarding tamoxifen.⁹ These findings indicate possible discordant perceptions of tamoxifen benefit between patients and providers. While physicians are trained to practice medicine in an evidence-based manner, patients' decisions may not be as objective. Accordingly, Donnelly found that patients tend to be influenced by their social groups.¹⁰ Donnelly also found that some women refused tamoxifen because it served as a constant reminder of their cancer risk.¹⁰ Thus, though an ongoing risk of cancer may encourage some to actively participate




FIGURE 1 Reasons for tamoxifen noninitiation




FIGURE 2 Reasons for tamoxifen noninitiation after a documented discussion with a healthcare provider

in prevention strategies, some women may approach this concern differently. To this end, Holmberg found that patients did not rely solely on a quantitative risk-benefit analysis when making decisions.¹¹ Instead, they incorporated their life experiences and approached decision-making in a more personally meaningful manner. These factors can pose a challenge to providers, as the communication of quantifiable information may not be adequate

to help patients make decisions regarding healthcare choices. A more tailored approach is warranted to ensure that the appropriate information is conveyed to the patient, which demands both clinical time and careful attention to individual patient concerns.

Fertility concerns are a unique aspect of the younger high-risk patient population that sets this cohort apart from older postmenopausal patients. For example, despite being viable strategies, embryo and oocyte preservation options were offered only about 39%-43% and 62%-63%, respectively, for eligible patients with breast cancer.¹² Furthermore, contrary to data establishing safety of ovarian stimulation, 42.1% of surveyed providers agreed to or were neutral about the statement that ovarian stimulation for embryo/oocyte preservation was not safe.¹² In our study, 10.4% of all patients that did not initiate tamoxifen chemoprevention stated their reason was fertility concerns. Among those patients that had a documented discussion about tamoxifen with their provider, the proportion of patients reporting fertility concerns was 16.7%. This finding may be associated with information regarding the teratogenicity of tamoxifen and the years long time frame for tamoxifen treatment. Accordingly, a desire for future fertility is an independent predictor of delayed or noninitiation of tamoxifen among patients diagnosed with breast cancer.¹³ These findings underscore the importance of education regarding options for fertility preservation for patients and providers confronting tamoxifen chemoprevention. A




FIGURE 3 Schematic approach to the management of young patients at high-risk for developing breast cancer

hiatus from tamoxifen to allow patients to become pregnant is also being studied.¹⁴ Early referral to a provider with specialization in reproductive endocrinology to facilitate the fertility preservation discussion is critical.

Another aspect of patient perceptions about tamoxifen identified in our study was the concern about side effects. Bober found a decrease in tamoxifen initiation among women of all ages concerned with side effects.¹⁵ Donnelly found the perceived impact of side effects to be a common theme among young patients accepting or declining tamoxifen.¹⁰ Interventions to minimize the side effects of tamoxifen utilizing medications such as venlafaxine could decrease discontinuation rates and help alleviate patient concerns regarding side effects.¹⁶

In terms of patient-physician communication, more than a third of the patients did not have a documented discussion with their provider regarding tamoxifen. A physician-led discussion is a major contributor to initiation of tamoxifen among patients, as the physician recommendation of tamoxifen has been associated with initiation.¹⁵ This effect also occurs at the primary care level, as a study by Taylor and Taguchi found the opinion of the family physician to play a role in the patients' decision to start tamoxifen.¹⁷ A lack of discussion by physicians may also be the result of a lack of provider knowledge.¹⁸ Kaplan found that a deficit in training was a barrier in tamoxifen prescription.¹⁹ That work also found that breast cancer risk reduction practices varied significantly based on the specialty of the primary treating provider.¹⁹ Collectively, these findings indicate areas for standardization of information and improved medical education regarding the nature of physician discussions, bias, and inherent perceptions about the risk/benefit associated with tamoxifen.

Patient decision-making is a complex process, and physicians must ensure that the patient's decision is informed. For this purpose, a multidisciplinary approach may be warranted in the management of young high-risk patients. Concerns over fertility or side effects could be alleviated through a comprehensive discussion and education. Through a team approach including oncologists, surgeons, and oncofertility specialists, many concerns about tamoxifen could be addressed. We propose an algorithm for the management of these patients that may help fill the gaps in communication between providers and patients (Figure 3). Patient decision-making is a highly individualized process. Providers should be equipped to discuss evidence-based data while also offering a patient-centered approach to care to ensure that patients are enabled to make most informed decisions possible.

ORCID

Pridvi Kandagatla  <https://orcid.org/0000-0002-4252-617X>

Kathryn Huber-Keener  <https://orcid.org/0000-0002-1981-7251>

REFERENCES

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. *J Natl Cancer Inst.* 1998;90:1371-1388.
2. Bevers TB, Armstrong DK, Arun B, et al. Breast cancer risk reduction. *J Natl Compr Canc Netw.* 2010;8:1112-1146.
3. Chlebowski RT, Col N, Winer EP, et al. American society of clinical oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. *J Clin Oncol.* 2002;20:3328-3343.
4. Nazarali SA, Narod SA. Tamoxifen for women at high risk of breast cancer. *Breast Cancer (Dove Med Press).* 2014;6:29-36.
5. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy in a cohort of 8769 early-stage breast cancer patients. *J Clin Oncol.* 2010;28:4120-4128.
6. Smith SG, Sestak I, Forster A, et al. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. *Ann Oncol.* 2016;27:575-590.
7. Bowles EJA, Buist DSM, Chubak J, et al. Endocrine therapy initiation from 2001 to 2008 varies by age at breast cancer diagnosis and tumor size. *J Oncol Pract.* 2012;8:113-120.
8. Fagerlin A, Dillard AJ, Smith DM, et al. Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid. *Breast Cancer Res Treat.* 2011;127:681-688.
9. Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. *Ann Surg Oncol.* 2001;8:580-585.
10. Donnelly LS, Evans DG, Wiseman J, et al. Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. *Br J Cancer.* 2014;110:1681-1687.
11. Holmberg C, Waters EA, Whitehouse K, Daly M, McCaskill-Stevens W. My lived experiences are more important than your probabilities: the role of individualized risk estimates for decision making about participation in the study of tamoxifen and raloxifene (STAR). *Med Decis Making.* 2015;35:1010-1022.
12. Lambertini M, Di Maio M, Poggio F, et al. Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. *Reprod Biomed Online.* 2019;38:835-844.
13. Llarena NC, Estevez SL, Tucker SL, Jeruss JS. Impact of fertility concerns on tamoxifen initiation and persistence. *J Natl Cancer Inst.* 2015;107.
14. Pagani O, Ruggeri M, Manunta S, et al. Pregnancy after breast cancer: are young patients willing to participate in clinical studies? *Breast.* 2015;24:201-207.
15. Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. *J Clin Oncol.* 2004;22:4951-4957.
16. Ramaswami R, Villarreal MD, Pitta DM, Carpenter JS, Stebbing J, Kalesan B. Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. *Breast Cancer Res Treat.* 2015;152:231-237.
17. Taylor R, Taguchi K. Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. *Ann Fam Med.* 2005;3:242-247.
18. Smith SG, Side L, Meisel SF, Horne R, Cuzick J, Wardle J. Clinician-reported barriers to implementing breast cancer chemoprevention in the UK: a qualitative investigation. *Public Health Genomics.* 2016;19:239-249.
19. Kaplan CP, Haas JS, Pérez-Stable EJ, Des Jarlais G, Gregorich SE. Factors affecting breast cancer risk reduction practices among California physicians. *Prev Med.* 2005;41:7-15.

How to cite this article: Kandagatla P, Rizk NN, Dokic D, et al. Patient and provider factors associated with the noninitiation of tamoxifen for young women at high-risk for the development of breast cancer. *Breast J.* 2020;26:464-468. <https://doi.org/10.1111/tbj.13528>